Richard C. Winneker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard C. Winneker has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Heather A. Harris
Women's Health and Musculoskeletal Biology, Wyeth Research, Collegeville, PA 19426, USA
2 shared publications - Judy S. Crabtree
Women's Health and Musculoskeletal Biology, Wyeth Research, Collegeville, USA
2 shared publications Puwen Zhang
2 shared publicationsZhiming Zhang
Endocrinology and Reproductive Disorders Division, Women's Health Research Institute
2 shared publicationsAndrew Fensome
1 shared publication- Andrew Fensome
Pfizer Research & Development , 1 Portland St
1 shared publication
Latest Publications
- Open Access
- 1 February 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (2) , 700-701
Effects of Various SERMs with or without Conjugated Estrogens on Mouse Mammary Gland
- 1 February 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (2) , 700-701
Open AccessEffects of Various SERMs with or without Conjugated Estrogens on Mouse Mammary Gland
- Open Access
- 25 June 2008
- Published by Springer Nature in BMC Medical Genomics
- Vol. 1 (1) , 27
Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman
Vaginal atrophy (VA) is the thinning of the vaginal epithelial lining, typically the result of lowered estrogen levels during menopause. Some of the consequences of VA include increased susceptibility to bacterial infection, pain during sexual intercourse, and vaginal burning or itching. Although estrogen treatment is highly effective, alternative therapies are also desired for women who are not candidates for post-menopausal hormone therapy (HT). The ovariectomized (OVX) rat is widely accepted as an appropriate animal model for many estrogen-dependent responses in humans; however, since reproductive biology can vary significantly between mammalian systems, this study examined how well the OVX rat recapitulates human biology.
- 25 June 2008
- Published by Springer Nature in BMC Medical Genomics
- Vol. 1 (1) , 27
Open AccessMolecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman
Vaginal atrophy (VA) is the thinning of the vaginal epithelial lining, typically the result of lowered estrogen levels during menopause. Some of the consequences of VA include increased susceptibility to bacterial infection, pain during sexual intercourse, and vaginal burning or itching. Although estrogen treatment is highly effective, alternative therapies are also desired for women who are not candidates for post-menopausal hormone therapy (HT). The ovariectomized (OVX) rat is widely accepted as an appropriate animal model for many estrogen-dependent responses in humans; however, since reproductive biology can vary significantly between mammalian systems, this study examined how well the OVX rat recapitulates human biology.
- 15 February 2005
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 23 (01) , 46-57
Nonsteroidal Progesterone Receptor Modulators: Structure Activity Relationships
Progesterone, acting primarily via the progesterone receptor (PR), plays an essential role in the regulation of female reproduction. Steroidal progestins (i.e., PR agonists) are commonly used in women's health, such as in contraception and hormone therapy and for the treatment of gynecological disorders. Recent studies in women and in nonhuman primates also indicate that PR antagonists may have potential applications in contraception and for the treatment of reproductive disorders such as fibroids and endometriosis. Currently, all clinically available PR agonists and antagonists are steroidal compounds. They often cause various side effects due to their functional interactions with other steroid receptors or because of effects associated with their steroidal metabolites. In an effort to identify more receptor-selective and structurally diverse compounds that may render clinical advantages over steroidal PR ligands, numerous receptor-selective novel nonsteroidal PR agonists and antagonists have been discovered. This review focuses on the structure activity relationships and the biological profile of the nonsteroidal PR modulators discovered in the last decade.
- 15 February 2005
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 23 (01) , 46-57
Nonsteroidal Progesterone Receptor Modulators: Structure Activity Relationships
Progesterone, acting primarily via the progesterone receptor (PR), plays an essential role in the regulation of female reproduction. Steroidal progestins (i.e., PR agonists) are commonly used in women's health, such as in contraception and hormone therapy and for the treatment of gynecological disorders. Recent studies in women and in nonhuman primates also indicate that PR antagonists may have potential applications in contraception and for the treatment of reproductive disorders such as fibroids and endometriosis. Currently, all clinically available PR agonists and antagonists are steroidal compounds. They often cause various side effects due to their functional interactions with other steroid receptors or because of effects associated with their steroidal metabolites. In an effort to identify more receptor-selective and structurally diverse compounds that may render clinical advantages over steroidal PR ligands, numerous receptor-selective novel nonsteroidal PR agonists and antagonists have been discovered. This review focuses on the structure activity relationships and the biological profile of the nonsteroidal PR modulators discovered in the last decade.